Reliance Chemotex Industries Dividend 2026 — ₹0.50 Final, 0.43% Yield

Incorporated in 1977, Reliance Chemotex Industries Limited is a Udaipur-based textile manufacturer that makes and sells synthetic and blended yarn. It is a micro-cap company with a market capitalisation of roughly ₹87 Cr and a single manufacturing base at Village Kanpur, Udaipur, Rajasthan.

The business sits in a cyclical, input-cost-sensitive part of the textile chain. Over FY26 it reported net sales of about ₹362 Cr with a thin net margin near 1.5%, which is typical for commodity yarn spinners. The promoter family holds 67.68%, and there is effectively no institutional ownership — FII and DII holdings are both 0% (source: exchange shareholding pattern, June 2026 quarter). That ownership profile keeps the free float small and trading volumes light.

The honest read on this Reliance Chemotex dividend is that it is a token payout, cut to a quarter of its earlier size. From ₹2.50 per share in FY22 and FY23, the final dividend dropped to ₹1.00 in FY24 and has settled at ₹0.50 for two years running. The ₹0.50 is comfortably affordable — it eats just 7.2% of FY26 profit — but the shrinking trend tracks the fall in earnings, not a deliberate shift to buybacks or reinvestment.

For yield-seekers, the number that matters is 0.43%, far below what a liquid fund or even a savings account pays. The dividend here is best seen as a signal of continuity from a 48-year-old promoter-run business, not as a source of income.

The company has not disclosed any forward dividend policy or target payout, so the future path is Not Disclosed by Company. What the data allows is a conditional read: with a payout of only 7.2% and earnings cover of 13.9x, the ₹0.50 dividend is easy to maintain even if profit stays thin.

The constraint is not affordability but priorities. Reliance Chemotex is in a heavy capex phase (FY26 investing outflow of about ₹81 Cr) funded largely by debt, with debt-to-equity near 1.90x. Until that capital cycle eases and returns improve, a meaningful dividend hike looks unlikely — though this is editorial reasoning from disclosed numbers, not a company forecast.

The Board of Reliance Chemotex Industries Limited recommended the final dividend of ₹0.50 per share for FY2025–26 at its meeting on 29 May 2026, alongside the audited annual results. In a separate filing dated 11 August 2026, the Board fixed the record date and book closure for the 48th Annual General Meeting and the dividend payment.

• Register of Members / Share Transfer Books closed: 18–24 September 2026 (both inclusive)
• Record date for dividend and AGM: 18 September 2026
• Cut-off date for e-voting: 18 September 2026
• Remote e-voting window: 21 September (9:00 AM) to 23 September 2026 (5:00 PM)

The dividend is subject to shareholder approval at the AGM, as is standard for a final dividend under the Companies Act, 2013.

This is where the face-value illusion bites. The dividend is often quoted as "5%," which is correct only against the ₹10 face value. The yield that a real investor earns is the dividend divided by the market price.

• Yield at current price (₹115): ₹0.50 ÷ ₹115 = 0.43%
• Yield at announcement-date price (~₹119): 0.42%
• Headline "5%" vs real yield: a ~11.5x overstatement

So a shareholder putting ₹1,00,000 into Reliance Chemotex shares at today's price would receive roughly ₹430 a year in dividend. The "5%" label describes the coupon on face value, not the return on money invested — a distinction retail investors frequently miss.

Reliance Chemotex has paid a final dividend every year for at least six years, which qualifies it as a consistent payer on frequency. On amount, however, the trend is clearly declining: ₹2.00 (FY21) → ₹2.50 (FY22, FY23) → ₹1.00 (FY24) → ₹0.50 (FY25, FY26).

There have been no special dividends, no interim dividends, and — importantly — no outright suspension or skip. The dividend was cut, not cancelled, as profits fell from ₹24 EPS in FY22 to ₹4–7 range thereafter. The pattern fits a cyclical business that protects a symbolic payout through down-years rather than a growth-dividend compounder. For FY26, holding ₹0.50 flat against a 30% profit rise signals caution, not confidence.

The operating-leverage story in FY26 is positive but narrow. Revenue was almost flat (+1% YoY to ₹362 Cr), yet operating profit rose 26% and PAT 30%. That gap means the improvement came from margin recovery and lower tax/deferred-tax drag, not from sales growth.

The longer lens is less flattering. Over five years sales growth has averaged a weak ~7% (5-yr) while the 3-year PAT CAGR is -25% (Source: Screener.in). Net margin at roughly 1.5% leaves almost no cushion: a modest rise in raw-material (polyester/viscose fibre) costs or power tariffs can wipe out the bottom line. The FY26 recovery is real but sits on a fragile margin base.

Reported profit is an opinion; cash is a fact — and here the two diverge. Operating cash flow is healthy relative to the dividend: FY26 OCF of roughly ₹18 Cr covers the tiny ₹0.38 Cr outflow about 48 times over.

The catch sits below OCF. The company spent heavily on investing activities — an FY26 investing outflow near ₹81 Cr — which pushes free cash flow deeply negative (roughly –₹64 Cr on our estimate). That capex was funded through financing inflows of about ₹60 Cr, i.e. fresh borrowing. In plain terms: the ₹0.50 dividend is paid out of operating accruals, but the company as a whole is cash-negative and adding debt, so the payout coexists with external funding needs. This is the kind of detail wire-service summaries skip.

On our four-test scorecard, the ₹0.50 Reliance Chemotex dividend scores well on the measures that matter at this size:

• Earnings coverage: 13.9x (payout 7.2%) — very strong
• OCF coverage: ~48x — very strong
• FCF coverage: negative FCF — fails this test
• Liquidity/cash: thin cash, high debt — weak

Verdict: Conditionally Sustainable. The payout is so small that earnings and operating cash flow cover it many times over, so a cut is unlikely on affordability grounds. The condition is that it coexists with negative free cash flow and rising debt — the dividend survives because it is tiny, not because the company is cash-rich.

With promoters holding 67.68%, the lion's share of the already-small payout flows to the promoter family. Of the total ~₹0.38 Cr dividend outflow, roughly ₹0.26 Cr goes to promoters and only about ₹0.12 Cr to all public shareholders combined.

Because there is no FII or DII holding, public shareholders are entirely retail. The dividend is distributed strictly in proportion to holding, so there is no structural bias — but the practical takeaway is that this payout is too small to move the needle for either group. For promoters it is a modest cash return on a controlling stake; for minority investors it is a few hundred rupees per lakh invested.

Since April 2020, dividends are taxed in the hands of the shareholder at their applicable income-tax slab rate — there is no separate Dividend Distribution Tax. The company deducts TDS at 10% only if total dividend paid to a resident shareholder in a financial year exceeds ₹10,000 (threshold raised from ₹5,000 effective FY2025–26). Without a valid PAN, TDS is 20%.

Worked Example

An investor holding 1,000 shares receives a gross dividend of ₹500 (1,000 × ₹0.50). This is below the ₹10,000 threshold, so no TDS is deducted. If the investor is in the 30% slab, tax payable is ₹150, leaving a net dividend of ₹350 — an effective post-tax yield on money invested of well under 0.3%.

The Reliance Chemotex FY2026 final dividend of ₹0.50 per share is a story of continuity, not income. The positives are real: an unbroken payout record, a wafer-thin 7.2% payout ratio, earnings cover of 13.9x, and a stock trading below book value. The negatives are equally clear: a real yield of just 0.43%, a dividend cut to a fifth of its FY23 level, negative free cash flow, and debt-to-equity near 1.90x.

For a pure dividend-income investor, the yield simply does not compete. For someone watching the business, the dividend is a small signal of promoter commitment through a weak earnings phase. We present the facts and the forensic detail — the decision stays with the reader.